Hyperbaric Oxygen Therapy Shows Promise for Post-Stroke Depression in New Randomized Trial

Macro 3D render of a single neuron synapse forming new connections with glowing oxygen particles, warm blue-to-amber tones symbolizing neuroplasticity and mood recovery

Depression after stroke is far more common than many realize. Roughly one-third of stroke survivors develop post-stroke depression (PSD), a condition that emerges not merely as an emotional response to disability but as a direct neurological consequence of brain injury. The symptoms—persistent sadness, loss of interest, fatigue, sleep disturbances, and cognitive slowing—often compound the physical impairments of stroke, creating a cycle that slows rehabilitation and worsens long-term outcomes. Standard treatments, primarily selective serotonin reuptake inhibitors and psychotherapy, help some patients but leave many others with residual symptoms.

Now, a new randomized controlled trial suggests that hyperbaric oxygen therapy (HBOT) may offer a path forward for at least some of these patients. The study, conducted in 2026 and reported in clinical summaries this month, found that stroke survivors randomized to HBOT experienced significant reductions in depression scores compared to those receiving sham treatment—with corresponding changes in biomarkers associated with brain repair.

The Burden of Post-Stroke Depression

Stroke is the leading cause of long-term disability worldwide, but the physical deficits—paralysis, speech difficulties, balance problems—are only part of the picture. The psychological aftermath can be equally disabling. Post-stroke depression typically emerges within the first three to six months after the event, though it can develop later. Its causes are multifactorial: direct damage to frontal-limbic circuits involved in mood regulation, inflammation, neurotransmitter dysregulation, and the psychological adjustment to sudden disability all play roles.

What makes PSD particularly challenging is its impact on recovery. Depressed patients are less likely to participate in physical therapy, adhere to medication regimens, or engage in social activities that support rehabilitation. They have higher rates of mortality and recurrent vascular events. Yet treatment remains inadequate for many. Antidepressants take weeks to work, carry side effects that elderly stroke survivors may not tolerate well, and appear less effective in PSD than in depression arising without brain injury.

The 2026 HBOT Trial: Design and Findings

The new study employed a rigorous sham-controlled design to test whether HBOT could address the biological underpinnings of post-stroke depression. Participants were randomized to receive either genuine hyperbaric oxygen therapy or a sham protocol designed to mimic the experience without delivering therapeutic pressure or oxygen levels. Neither patients nor assessors knew which treatment was being administered.

The results, measured at two and four weeks of treatment, showed a clear separation between groups. Patients receiving genuine HBOT demonstrated statistically significant reductions on the Hamilton Depression Rating Scale (HAMD), a standard clinical measure of depression severity. The sham group showed minimal change. Perhaps more intriguingly, the researchers observed corresponding increases in brain-derived neurotrophic factor (BDNF) and β-nerve growth factor (β-NGF)—proteins that support neuronal survival, growth, and synaptic plasticity.

These biomarker changes matter because they suggest a mechanism. HBOT is not merely producing a placebo effect or temporary mood elevation. The therapy involves breathing 100 percent oxygen in a pressurized chamber, typically at 1.5 to 2.0 atmospheres absolute. Under these conditions, the amount of oxygen dissolved in plasma increases dramatically—enough to oxygenate tissues even without hemoglobin. For brain regions rendered ischemic but not destroyed by stroke, this oxygen surge may support cellular metabolism, reduce inflammation, and stimulate the growth of new blood vessels and neural connections.

Building on Earlier Cognitive Evidence

The depression trial builds on earlier work from the same research group at the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center in Israel. In 2024, Dr. Shai Efrati and colleagues published findings from a randomized controlled trial of HBOT for post-stroke cognitive impairment. That study demonstrated significant improvements in memory, attention, and information processing speed—even in patients whose strokes occurred months or years earlier.

The cognitive trial was notable for its use of both behavioral measures and brain imaging. Participants showed increased activity and connectivity in regions associated with cognitive function, and the improvements correlated with changes in cerebral blood flow. The implication—that the brain retains latent capacity for repair long after the acute phase of stroke—challenged the traditional view that neural recovery plateaus within weeks or months.

The new depression data extend this narrative. If HBOT can simultaneously address cognitive impairment and mood disturbance—two of the most common and debilitating post-stroke sequelae—it could represent a significant advance in rehabilitation medicine. The biomarker findings suggest that both effects may stem from a common mechanism: the restoration of metabolic function and the promotion of neuroplasticity in damaged but viable brain tissue.

The FDA Perspective: Why Clearance Remains Distant

Despite these encouraging findings, hyperbaric oxygen therapy remains firmly outside the FDA-cleared indications for stroke or depression. The agency’s list of approved uses includes decompression sickness, carbon monoxide poisoning, certain non-healing wounds, gas gangrene, crush injuries, and late radiation tissue injury—conditions where the physiological rationale is well-established and the evidence base meets regulatory standards. Stroke and its psychiatric complications are not on that list.

The FDA has been explicit about its position on off-label HBOT use. In consumer guidance, the agency warns that “hyperbaric oxygen therapy has not been clinically proven to cure or be effective in the treatment of” a range of conditions including stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and depression. The 2025 safety communication to healthcare providers reinforced this message while adding new urgency about device risks—particularly fire hazards in chambers that do not meet safety standards or are operated outside clinical settings.

For researchers and clinicians in the field, the regulatory stance is not a dismissal of biological plausibility but a reflection of evidentiary standards. The randomized trials conducted to date, while promising, are relatively small and single-center. The depression trial appears to follow this pattern. Regulatory approval typically requires larger, multi-center studies with standardized protocols and longer follow-up periods to establish durability of benefit and characterize risks across diverse populations.

Safety Considerations and Practical Realities

Even for patients intrigued by the research, accessing HBOT for post-stroke depression presents challenges. Because the indication is not FDA-cleared, insurance coverage is essentially nonexistent. Patients would need to pay out of pocket—often thousands of dollars for a course of 20 to 40 sessions. And they would need to find a facility willing to treat them off-label, which reputable centers may be reluctant to do given the liability and regulatory environment.

The safety profile of HBOT, when properly administered, is generally favorable. Barotrauma to the ears or sinuses, temporary nearsightedness, and claustrophobia are the most common issues. Oxygen toxicity seizures are rare at the pressures used for neurological indications. But the 2025 FDA safety communication highlighted a more serious concern: fire risk in chambers that are not properly maintained, operated by inadequately trained staff, or used in non-clinical settings such as homes or wellness centers. The death of a child in a hyperbaric chamber fire in Michigan in January 2025 underscored that these risks are not theoretical.

For stroke survivors specifically, there are additional considerations. Patients with uncontrolled seizures, certain types of lung disease, or recent ear surgery may not be candidates for HBOT. The treatment requires the ability to equalize pressure in the ears, which some elderly patients find difficult. And the time commitment—daily sessions of 60 to 90 minutes for several weeks—can be burdensome for those with mobility limitations.

What Comes Next

The 2026 depression trial adds to a growing body of literature suggesting that hyperbaric oxygen therapy may have broader neurological applications than its current FDA clearances reflect. The combination of clinical improvement and biomarker changes in a randomized, controlled setting is the kind of evidence that moves a field forward. But it is not yet the kind of evidence that changes standard of care.

For now, stroke survivors with depression should work with their physicians to optimize established treatments—antidepressants, psychotherapy, and structured rehabilitation programs. Those interested in HBOT should understand that it remains investigational for this indication, that access is limited and costly, and that the decision to pursue it should be made with clear-eyed consideration of both potential benefits and uncertainties.

The research trajectory, however, is clear. If larger trials confirm these findings and elucidate which patients are most likely to benefit, hyperbaric oxygen therapy could eventually find its place in the post-stroke rehabilitation toolkit. For a condition as common and debilitating as post-stroke depression, that would be a welcome addition.

Sources

← Back to blog